Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Market Closed - Sao Paulo
Other stock markets
 10:04:14 2024-07-11 am EDT 		5-day change 1st Jan Change
186.3 BRL +1.07% Intraday chart for Gilead Sciences, Inc. +2.29% -3.25%
Jul. 11 Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 MT
Jul. 09 RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia
CI
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer
CI
Top Premarket Gainers
MT
Wall Street futures edge lower ahead of business survey data
RE
Equity Markets Close Mixed as Investors Weigh Economic Data
MT
Equity Markets Close Mixed After Macro Data
MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup
DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data
MT
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon
MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower
MT
Sector Update: Health Care
MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention
MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial
DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study
RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial
CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup
DJ
EU regulator mandates label updates on CAR-T cancer therapies
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. News Gilead Sciences, Inc.
  6. Highlights